ESA (epoetin alfa or darbepoetin) — MDS-LR symptomatic anemia 1L
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-EPOETIN-ALFA |
|---|
| ID | REG-ESA-MDS-LR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Notes
1L for MDS-LR symptomatic anemia if endogenous EPO ≤500 mU/mL AND RBC TD ≤2U/month — response rate ~50-60% in this selected population. Add G-CSF in non-responders if RS-MDS subtype. Target Hb 10-12 g/dL (do NOT exceed). Switch to luspatercept (MEDALIST: RS-MDS post-ESA; COMMANDS: 1L LR-MDS broadly) or lenalidomide (del 5q) on failure. STUB — requires clinical co-lead signoff before publication.
Used By
Indication
IND-MDS-LR-1L-ESA- IND-MDS-LR-1L-ESA